Dosed first patient in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCClinical data on track for…
TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…
The Canadian startup has gained exclusive access to the U.S. accelerator, including funding, resources, and engagement with world-renowned health organizationsTORONTO--(BUSINESS…
TORONTO, ON / ACCESSWIRE / March 11, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical…
– STRIDE Phase 2 primary endpoint of PASI 75 and key secondary endpoints met at all clinically relevant doses tested;…
- Cerebrospinal fluid (CSF) biomarker results are highly supportive of sabirnetug’s downstream pharmacological effects in the brain in early AD…
Global Premiere Set for March 22 at Cinema Village in Greenwich Village, NYC ARLINGTON, Va., March 7, 2024 /PRNewswire/ --…
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world’s first…
MINNEAPOLIS, March 7, 2024 /PRNewswire/ -- People who have headaches after experiencing concussions may also be more likely to have…
Masimo Stork™ and Bowers & Wilkins Garner Six Prestigious Accolades Across Multiple CategoriesIRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) is proud to…